MedTrace Logo

Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions

NCT01003106 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2016-03-15

Study results available
· View outcomes & findings →

Summary

The primary Objective of this study is to evaluate the safety and tolerability of intraocular injections of 0.5mg or 2.0mg of ranibizumab in patients with macular edema due to retinal vein occlusion.

Conditions

  • Retinal Vein Occlusion

Interventions

DRUG

Ranibizumab 0.5mg (monthly)

Branch retinal vein occlusion- Intravitreal injection of 0.5mg ranibizumab alone

DRUG

Ranibizumab 2.0mg (monthly)

DRUG

Pro re nata (prn) ranibizumab

PROCEDURE

Pro re nata (prn) Laser photocoagulation

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Peter A Campochiaro, MD

    lead OTHER

Principal Investigators

  • Peter A Campochiaro, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01003106 on ClinicalTrials.gov